CDIO
Cardio Diagnostics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CDIO
Cardio Diagnostics Holdings,Inc.
A biotechnology company that develops cloud-based cardiac monitoring system for cardiovascular disease prevention
Biological Technology
09/06/2019
01/14/2022
NASDAQ Stock Exchange
13
12-31
Common stock
311 West Superior Street, Suite 444, Chicago, IL 60654
--
Cardio Diagnostics Holdings, Inc., was incorporated under the laws of the State of Delaware on September 6, 2019. Cardio Diagnostics is a biotechnology company dedicated to making the prevention and early detection of cardiovascular disease more accessible, personalized and precise. Cardio was established to further develop and commercialize a proprietary artificial intelligence-driven integrated genetic-epigenetic EngineTM for cardiovascular disease, becoming one of the leading medical technology companies capable of improving the prevention, early detection and adjuvant treatment of cardiovascular disease.
Company Financials
EPS
CDIO has released its 2023 Q3 earnings. EPS was reported at -0.16, versus the expected -0.27, beating expectations. The chart below visualizes how CDIO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CDIO has released its 2025 Q1 earnings report, with revenue of 940, reflecting a YoY change of -94.10%, and net profit of -1.64M, showing a YoY change of 60.73%. The Sankey diagram below clearly presents CDIO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
